Core 1: Administrative Core

项目摘要-核心1 -管理核心Dana-Farber癌症研究所 该提案汇集了达纳-法伯癌症研究所的转化医学和研究专业知识 （DFCI），Dana Farber/哈佛癌症中心和马萨诸塞州理工学院（MIT）与临床 法国法语国家骨髓瘤研究小组（IFM）的研究力量， 毫米在这一国际合作更新申请中，我们现在建议建立在我们非常成功的基础上， 基因组、临床前、临床和管理优势，以解决下一代问题， 最终导致治愈的治疗进展。最重要的是，我们目前的研究证实， 自体干细胞移植后的美法仑剂量治疗达到MRD阴性状态，并导致 显著上级生存结局。在本提案中，我们现在将进行一项合作试验，以解决 下一个最重要的问题是MRD状态如何告知我们的治疗决策算法（项目1）。 重要的是，来自统一治疗的患者的大量样本将使我们能够识别基因组 疾病行为的表观基因组相关性;主转录因子和致癌浓缩物的作用 （项目2）：识别长非编码RNA依赖性并验证新型靶向治疗方法 （项目3）;并定义MM中基因组不稳定性的机制和临床意义（项目4）。这 独特的国际合作努力需要大量的努力协调，战略整合， 监测和监督各种职能，以及各分散地点调查员之间的沟通 网站.核心A的主要功能是整合研究工作和研究者之间的沟通。 科学和行政一体化对于确保四个项目之间的成功互动至关重要， 以及在这个多国多部门的项目内和项目之间的实验室和临床组成部分之间， 机构方案。因此，这个中心核心将提供各种项目之间的联系， 协调临床研究和拟议的相关科学。为了帮助实现这些目标，核心A将： 监测临床研究的及时实施，并确保组织采集、处理和使用的进展 协调临床和相关科学研究之间的相互作用（具体目标1）;协调 各国际研究中心研究者之间的通信和数据交换（具体目标2）; 为项目和核心（具体目标）提供必要的资源、财政监督和行政支持 3）;促进方案内互动、会议、旅行以及内部和外部咨询委员会 （具体目标4）。

Project Summary – Core 1 – Administrative Core Dana-Farber Cancer Institute This proposal brings together the translational medicine and research expertise of Dana-Farber Cancer Institute (DFCI), Dana Farber/Harvard Cancer Center, and Massachusetts Institute of Technology (MIT) with the clinical research strength of Intergroupe Francophone du Myeloma (IFM) in France to develop a curative strategy for MM. In this international collaborative renewal application, we now propose to build on our highly successful genomic, preclinical, clinical, and administrative strengths to address the next generation of questions that will ultimately lead to therapeutic advances for cure. Most importantly, our current study has confirmed that high dose melphalan treatment followed autologous stem cell transplant achieves MRD negative status and leads to significantly superior survival outcome. In this proposal, we will now undertake an a collaborative trial to address the next most important issue of how MRD status will inform our therapeutic decision algorithm (Project 1). Importantly, the large number of samples from uniformly treated patients will allow us to both identify genomic and epigenomic correlates of disease behavior; role of master transcription factors and oncogenic condensates (Project 2); identify long non coding RNA dependencies and validate novel targeted therapeutic approaches (Project 3); and define the mechanisms and clinical implications of genomic instability in MM (Project 4). This unique international collaborative effort requires significant co-ordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between investigators at various dispersed sites. The key function of Core A is integration of the research efforts and communication between investigators. Scientific and administrative integration is essential to assure successful interaction between the four Projects, as well as between the laboratory and clinical components within and between projects in this multinational multi- institutional program. Therefore, this central core will provide the link between various projects and successfully co-ordinate the clinical study and the proposed correlative science. To aid in achieving these goals, Core A will: monitor the timely conduct of the clinical study and assure progress in tissue collection, processing and usage to co-ordinate interaction between the clinical and correlative science studies (Specific Aim 1); co-ordinate communication, and exchange of data between investigators at various international sites (Specific Aim 2); provide necessary resources, fiscal oversight and administrative support for projects and cores (Specific Aim 3); facilitate intra-programmatic interactions, meetings, travel and Internal and External Advisory Committees (Specific Aim 4).